Summary

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Dermatology, Respiratory, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders and Oncology which include indications Atopic Dermatitis (Atopic Eczema), Inflammation, Non-Alcoholic Steatohepatitis (NASH), Celiac Disease, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Kidney Fibrosis, Obesity, Psoriasis, Pulmonary Fibrosis, Pulmonary Hypertension and Type 2 Diabetes.

The latest report Proteinase Activated Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.


Scope

  • The report provides a snapshot of the global therapeutic landscape for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)
  • The report reviews Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics




Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope